Ken Griffin Johnson & Johnson Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$144.38 - $157.78 $72.7 Million - $79.4 Million	-503,200 Reduced 15.98%	2,646,100 $387 Million
Q1 2024 May 15, 2024	SELL	$155.22 - $162.74 $91.5 Million - $96 Million	-589,600 Reduced 15.77%	3,149,300 $498 Million
Q4 2023 Feb 14, 2024	BUY	$145.6 - $158.88 $29.1 Million - $31.7 Million	199,800 Added 5.65%	3,738,900 $586 Million
Q3 2023 Nov 14, 2023	SELL	$155.75 - $174.48 $86.5 Million - $96.9 Million	-555,400 Reduced 13.56%	3,539,100 $551 Million
Q2 2023 Aug 14, 2023	SELL	$154.35 - $166.11 $119 Million - $128 Million	-771,000 Reduced 15.85%	4,094,500 $678 Million
Q1 2023 May 15, 2023	BUY	$151.05 - $180.26 $20.6 Million - $24.6 Million	136,400 Added 2.88%	4,865,500 $754 Million
Q4 2022 Feb 14, 2023	SELL	$160.2 - $179.79 $83.4 Million - $93.6 Million	-520,500 Reduced 9.92%	4,729,100 $835 Million
Q3 2022 Nov 14, 2022	BUY	$161.33 - $179.52 $281 Million - $313 Million	1,744,000 Added 49.75%	5,249,600 $858 Million

4,227

1.7B

12.5M

10.3M

Ticker JNJ
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,614,479,872
Market Cap $410B
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.